MabVax Therapeutics Holdings Inc
MabVax Therapeutics — BIO CEO 2017 Investor Conference
41 slides from MabVax Therapeutics's conference presentation, Feb 13, 2017

Slide 1: MabVax Therapeutics - BIO CEO 2017 Investor Conference Presentation
NASDAQ: MBVX WY, | MabVax therapeutics Clinical Stage Immuno-Oncology Company Developing Products from the Human Immune Response to Cancer BIO CEO 2017 Investor Conference Presentation

Slide 2: Disclaimer: Forward Looking Statements
DISCLAIMER Forward Looking Statements This presentation contains forward-looking statements and projections. The company makes no express or implied representation or warranty as to the completeness of this information or, in the case of the projections, as to their attainability or the accuracy and

Slide 3: MabVax Overview
MABVAX OVERVIEW ¢ HuMab Discovery Platform: antibody-based products derived from the human immune response to cancer — Developed platform for antibody discovery resulting in portfolio of fully human antibodies — Integrated approach to development of a companion diagnostic with a therapeutic treatmen

Slide 4: MabVax Overview: Key Pipeline Assets
MABVAX OVERVIEW: KEY PIPELINE ASSETS REPORT POSITIVE MILESTONES @ MVT-5873 Therapeutic Phase I: Interim safety established — Dosage levels cleared support full platform development — MVT-5873 demonstrates potential to convert approximately one third of patients to stable disease for four or more cyc

Slide 5: Sialyl Lewis A as a Viable Target for Cancer Therapeutics
SIALYL LEWIs4 — AS A VIABLE TARGET FOR CANCER THERAPEUTICS ¢@ HuMab-5B1 derived from a patient vaccinated with MabVax vaccine licensed from MSKCC CA19-9 detection in patients 4 @ Sialyl Lewis A antigen (SLEA or CA19-9) is the most frequently utilized and only Pancreas 92 validated serum marker for a

Slide 6: Summary of Preclinical Data
SUMMARY OF PRECLINICAL DATA M MabVax NASDAQ: MBVX therapeutics 6

Slide 7: HuMab-5B1 Is Highly Specific to sLeA Antigen by Glycan Array Analysis
HUMAB-5B1 Is HIGHLY SPECIFIC TO SLE* ANTIGEN BY GLYCAN ARRAY ANALYSIS Against a glycan array! of 465 distinct carbohydrates, HuMab-5B1 binds with specificity to both major sLe* isoforms MVT-5873 (5B1) at 10ug/mL 40000 isLe* (Ac) sle* (Ge) 2 30000 & z 2 i @ a 10000 sle*-Let ° + ' + ° so | tol sol 200

Slide 8: HuMab-5B1 Antibody Target Significantly Overexpressed on Multiple Cancers
HUMAB-5B1 ANTIBODY TARGET SIGNIFICANTLY OVEREXPRESSED ON MULTIPLE CANCERS Potential therapeutic utility extends beyond pancreatic cancer A. Pancreatic ductal adenocarcinoma & B. Colon carcinoma C. Lung adenocarcinoma D. Urinary bladder, mucinous adenocarcinoma E. Colon metastatic to ovary F. Breast

Slide 9: MVT-5873 Demonstrates Synergistic Anti-Tumor Effect with Chemotherapy
MVT-5873 DEMONSTRATES SYNERGISTIC ANTI- TUMOR EFFECT WITH CHEMOTHERAPY IN MULTIPLE CANCER MODELS Relative Tumor Growth at Day 42 Relative Tumor Volume at Day 52 Gemcitabine/nab-Paclitaxel as Baseline BxPC3 Pancreatic Xenograft Model Paclitaxel as Baseline DMS 79 SCLC Xenograft Model 2500 ° "we Hu Ig

Slide 10: MVT-5873 Clinical Program Summary and Interim Data
MVT-5873 CLINICAL PROGRAM SUMMARY AND INTERIM DATA M MabVax NASDAQ: MBVX therapeutics 10

Slide 11: MVT-5873 Phase I Trial for PDAC & CA19-9 Positive Cancer
MV7T-5873 PHASE I TRIAL FOR PDAC & CA19-9 POSITIVE CANCER Open label, non-Randomized, Dose Escalation/Expansion Study Part 1: Single Agent Dose Escalation Part 2: Combination with Chemotherapy (gemcitabine/nab-paclitaxel) Stage 3 and 4 Patients With Progressive Disease Who Have Newly Diagnosed Treat

Slide 12: Interim MVT-5873 Pharmacokinetics Analysis
INTERIM MVT-5873 PHARMACOKINETICS ANALYSIS PARAMETERS SIMILAR TO OTHER THERAPEUTIC ANTIBODIES ¢ The study is evaluating the pharmacokinetics of MVT-5873 in all cohorts ¢ Initial pharmacokinetic analysis includes evaluating different schedules of administration using a two-compartment model ¢@ MVT-58

Slide 13: Interim Analysis Shows MVT-5873 Normalizes CA19-9 Levels
INTERIM ANALYSIS SHOWS MVT-5873 NORMALIZES CA19-9 LEVELS IN PANCREATIC CANCER PATIENTS Circulating Levels of Antigen Normalized at Modest Doses of Antibody # CA19-9 normalization post MVT- 1mg/kg 2mg/kg 5873 administration appears to be Per Dose Per Dose Pre-Dose Levels dose dependent ¢# 1 mg/kg MVT

Slide 14: Clinical Results to Date by Patient
CLINICAL RESULTS TO DATE (01/05/17) BY PATIENT CONVERSION OF PROGRESSIVE TO STABLE DISEASE Patient # r 002 [2 Teyele RECIST 1. Safe | 003 | 2mg/kg/cycle | 004 | 2mg/kg/eyele fl] RECIST 11 RECIST 11 006 | 6 mg/kg/cycle > 008 | 2mg/kg/cycle Safe | 009 | 2mg/I cle 012 [2mg/ke/evele f- 014 [J Patient on

Slide 15: Unmet Clinical Need for Adjuvant Therapy
UNMET CLINICAL NEED FOR ADJUVANT THERAPY ¢ Unmet Need for Maintenance Therapy after Successful Chemotherapy Regimens — No product currently approved for or standardized treatment regimen defined for maintenance — Significant toxicities with continuing chemotherapy limit continued use — No medical ra

Slide 16: MVT-2163 Clinical Program Summary and Interim Data
MVT-2163 CLINICAL PROGRAM SUMMARY AND INTERIM DATA M MabVax NASDAQ: MBVX therapeutics 16

Slide 17: MVT-2163 Preclinical Development Efforts Translated into Positive Clinical Results
MVT-2163 PRECLINICAL DEVELOPMENT EFFORTS HAVE TRANSLATED INTO POSITIVE CLINICAL RESULTS ¢ Based on in-depth review of clinical literature and input from thought leaders MabVax developed a rationale for a translational preclinical development plan to define: — Time required to obtain optimal scan ima

Slide 18: MVT-2163 Imaging Compared to Standard PET Agent
MVT-2163 IMAGING COMPARED TO STANDARD PET AGENT Mice orthotopically transplanted with BxPC3-luc pancreatic tumor xenografts JNM Rivers ‘The co-tegistration of FDG-PET and computed Acquired "Zr radiolabed-5B1 antibody (*°Z-5B1) tomography (CT) (left) and planar sections of PET image of the same mouse

Slide 19: Tumor Targeting in Shedding and Non-Shedding CA19-9 Models
EFFICIENT ®8°ZR-HUMAB-5B1 TUMOR TARGETING OCCURS IN BOTH SHEDDING AND NON-SHEDDING CA19-9 MODELS DMS79 (SCLC) Does not shed detectable CA 19-9 2h 24h 48h 96h 120h Colo205 (Colon Cancer) High levels of shed antigen ~2300 U/ml for a 250mm? tumor Viola-Villegas, JNucMed 2013 \\/ NASDAQ: MBVX | 19 Wy th

Slide 20: MVT-5873 Pre-Administration Improves MVT-2163 PET Image Quality
MVT-5873 PRE-ADMINISTRATION IMPROVES MVT-2163 PET IMAGE QUALITY Ne ete? }- . Inject radiolabeled antibody Sl “as : Tumor Cells. Zr-SB1 en) uptake and Tumor ir Interval between injections Gsm Oth B4n B24sh_ — No“cold” oa i ay Nae cs ye poor contrast ] 2 a Inject x unlabeled antibody ~=7 Vt I sd lj In

Slide 21: Phase I Trial Design of MVT-2163 ImmunoPET Imaging Agent
PHASE I TRIAL DESIGN OF MVT-2163 IMMUNOPET IMAGING AGENT PANCREATIC CANCER AND OTHER CA19-9 MALIGNANCIES Open label, non-randomized, dose escalation/expansion study Patients can roll to MVT-5873 Monotherapy Trial lation and . Part 1: Dose Escalation Pareds Be Image Optimization MVT-2163 dosed alone,

Slide 22: Background: Comparable Antibody Therapies for Cancer Diagnosis and Treatment
BACKGROUND: COMPARABLE ANTIBODY THERAPIES FOR CANCER DIAGNOSIS AND TREATMENT 8°Z1-Trastuzumab for metastatic M1J-J591 for hormone Minibody *-Zr-DF IAB2M, breast cancer refractory prostate cancer 50mg pre-administration a —_— b _ ce = j ! 4 { w i q | | ; ; 1 day ‘2 days 5 days ie — ba] ena Accumulati

Slide 23: 89Zr-DFO-HuMab5B1 (MVT-2163): Patient #10
8°ZR-DFO-HUMAB5B1 (MVT-2163): PATIENT #10 Dose Level: 50mg/5 mCi (actual 4.43 mCi) + 47 mg Blocking Dose Patient: Female 158cm/64.2kg Pre-Dose CA19-9 = 2119 IU/mL, Post Dose CA19-9 = 51 IU/mL 7 ee 2 ae mom f 1h 20h 44h 141h Mi MabVax NASDAQ: MBVX therapeutics 23.

Slide 24: Patient Example: MVT-2163 PET Images
PATIENT EXAMPLE: MVT-2163 PET IMAGES LIVER METASTASIS AT HIGH SUV AS EARLY AS Day 1 POST DOSE MVT-2163 PET & Diagnostic CT Image Correlation Demonstrating Target Specificity Liver metastases SUVmax 75.2, Multiple nodes SUVmax 10.2 MVT-5873 47mg then 2h delay time MVT-2163 PET PET / Cr | 20h 141h Dia

Slide 25: MVT-2163 Product Opportunity
MVT-2163 PRODUCT OPPORTUNITY ¢ Critical unmet medical need for correctly staging newly diagnosed PDAC patients for surgery — Only 20% deemed eligible for surgery — Incomplete disease dissemination identification — CF resolution limited to approximately 1 cm with many metastatic lesions less than 1 c

Slide 26: MVT-1075 Program Summary and Product Opportunity
MVT-1075 PROGRAM SUMMARY AND PRODUCT OPPORTUNITY M MabVax NASDAQ: MBVX therapeutics 26

Slide 27: MVT-1075 Radioimmunotherapy - Preclinical Tumor Growth Suppression and Regression
MVT-1075 RADIOIMMUNOTHERAPY — PRECLINICAL STUDIES DEMONSTRATE SUBSTANTIAL TUMOR GROWTH SUPPRESSION AND TUMOR REGRESSION fe 377Lu-CHX-A"-DTPA-5B1 Biodistribution of !”7 Lu-CHX-A”-DTPA-5B1 © Control (PBS) = 5B1 2 set df 130 2 = 300uCi 120 & io] * RO 110. , Bth 3 400 3 N=8 for all groups ° 80 2 ry es B

Slide 28: MVT-1075 HuMab-5B1 Radioimmunotherapy: Orthotopic PDAC Model
MVT-1075 HUMAB-5B1 RADIOIMMUNOTHERAPY ORTHOTOPIC PDAC MODEL DEMONSTRATES TUMOR REGRESSION BO Pre-treatment Post-treatment Collaboration with Jason S. Lewis, Ph.D. Member, Memorial Sloan-Kettering Cancer Center, Mi Vice Chairman & Chief Attending, Department of Radiology MabVax NASDAQ: MBVX

Slide 29: Manufacturing, Quality, Distribution Established for Clinical Program
MANUFACTURING, QUALITY, DISTRIBUTION ESTABLISHED FOR CLINICAL PROGRAM AND PATHWAY FOR COMMERCIALIZATION ¢@ MVT-1075 manufactured on a per patient basis ¢ Manufacturing established at experienced cGMP third party site ¢ Produced from a bulk conjugate intermediate as unit of use vials @ Process simila

Slide 30: Phase I Trial of MVT-1075 Radioimmunotherapy
PHASE I TRIAL OF MVT-1075 RADIOIMMUNOTHERAPY FOR PANCREATIC AND OTHER CA19-9 MALIGNANCIES Open label, Non-randomized, Dose Escalation Safety Study blish Safety, Tolerability, Dosimetry & RP2D o-administration MVT-1075 fractional dose Phase I Dose E ion and Expansion Histologically confirmed, 3 study

Slide 31: MVT-1075 Product Opportunity
MVT-1075 PRODUCT OPPORTUNITY ¢ Reduce disease burden by making more patients eligible for surgery — Given to newly diagnosed patients either before or after chemotherapy to reduce primary tumor size/spread and eliminate metastatic sites ¢ Applicable for multiple cancer types that are positive for CA

Slide 32: Market Opportunity for HuMab 5B1
MARKET OPPORTUNITY FOR HUMAB 5B1 — REPRESENTS POTENTIAL NEW TREATMENTS FOR MULTIPLE CANCERS Pancreatic Colon & Rectum Small Cell Lung Cancer Stomach Mi MabVax therapeutics 53,070 134,490 30,143 26,370 41,780 7.7% 49,119 65% 20,100 14% 10,730 31% ' Global Data Disease Reports Deaths Yr Aarket Opportu

Slide 33: Partnering Discussions
PARTNERING DISCUSSIONS ¢ Active discussions with potential partners under CDA in progress. Multiple opportunities ¢ Antibody as targeting vehicle for development of a bi-specific, ADC or CAR-T product — Multiple domestic and Asian companies — Multiple indications ¢ Radioimmunotherapy product — Multi

Slide 34: Key Milestones for HuMab5B1 Development Programs
Key MILESTONES FOR HUMAB5B1 DEVELOPMENT PROGRAMS FOR 2016 AND 2017 lopment Program MVT-5873 Therapeutic Monotherapy MVT-5873 Therapeutic Combination with Chemo MVT-2163 PET Imaging MVT-1075 Radio- Immunotherapy HuMab-5B1 ADC Mi MabVax therapeutics 1H2016 escalation safety Phase I Trial Initiate dose

Slide 35: MabVax Has Rich Pipeline of Potential Antibody Products
MABVAX HAs RICH PIPELINE OF POTENTIAL ANTIBODY PRODUCTS — , Lead Pre- Commercial Target Programs Indications Discovery Op IND Phase I Phase II Rights Monoclonal Antibody Ps MVT-5873 Therapeutic MVT-2163 Pancreatic and . __, PET Imaging Agent other CA19-9 Sialyl Lewis* \gy7-1075 positive ww Radioimmu

Slide 36: Robust Intellectual Property
ROBUST INTELLECTUAL PROPERTY 14 issued patents and 3 pending applications in the U.S. ¢ 13 issued US patents and 1 pending US application covering monovalent and polyvalent vaccines, methods of manufacture, methods of use ¢ 1 issued US patent and 2 pending US applications covering monoclonal antibod

Slide 37: Strong Management Team and Board of Directors
STRONG MANAGEMENT TEAM AND BOARD OF DIRECTORS J. David Hansen Founder, President & CEO Board Member Philip Livingston, M.D. Founder & Chief Science Officer Gregory Hanson Chief Financial Officer Wolfgang Scholz, Ph.D. Founder & Vice President Antibody Discovery Paul Maffuid, Ph.D. Executive Vice Pre

Slide 38: Capitalization Table / Financial Statistics
CAPITALIZATION TABLE/ FINANCIAL STATISTICS Security Common Shares - Outstanding = 6.3M Preferred Stock — Common Equivalents ($0.01 Liquidation Preference) 7 20M Subtotal - 9.3M Restricted Stock Units — Outstanding and Unvested - 0.2M Warrants - Outstanding $6.84 5.1M Stock Options — Outstanding and

Slide 39: Market Statistics
MARKET STATISTICS* Stock Symbol: MBVX (Nasdaq Capital Market) Closing Price: $2.85 on February 10, 2017 52 Week High/Low: $6.05/$2.62 3-Month Average Daily Volume/Liquidity 53,540/$153,000™ Shares Outstanding: 6.3 Million™ Market Cap: $18.0 Million” Float: 6.0 Million Free Trading Shares *Price & Vo

Slide 40: Investment Thesis: Poised for Near Term Growth
INVESTMENT THESIS: POISED FOR NEAR TERM GROWTH Comparative Market Valuations with Similar Early Stage Immuno-Oncology Companies Valuation Drivers * # Projects * Stage of development * Market opportunity * Partnerships Market Capitalization MabVax Opportunity * Successful interim phase 1 . results Co

Slide 41: Company Contacts
Mi MabVax therapeutics Immuno-Oncology Products Discovered From The Human Immune Response to Cancer Company Contacts J. David Hansen Gregory P. Hanson CMA MBA President and CEO Chief Financial Officer [email protected] [email protected] 858-500-8455 858-500-8457 Mu Vax NASDAQ: MBVX | 41
Source: SEC EDGAR · 8-K filed Feb 13, 2017
More decks from MabVax Therapeutics Holdings Inc
Investor Presentation (October 2018)19 slides · Oct 22, 2018
Virtual Investor Conference (May 2018)25 slides · May 3, 2018
Investor Presentation (February 2018)24 slides · Feb 12, 2018
Investor Presentation (September 2017)33 slides · Sep 12, 2017
Investor Presentation (August 2017)33 slides · Aug 24, 2017
Investor Presentation (June 2017)23 slides · Jun 23, 2017